Home / Health / AI Test Accurately Predicts Low-Risk Breast Cancer
AI Test Accurately Predicts Low-Risk Breast Cancer
22 Oct
Summary
- AI test identified nearly a quarter of patients as low risk.
- Low-risk patients had 96.1% recurrence-free survival at 10 years.
- Test uses AI with pathology slides and clinical data.
An AI-powered test, myStage Dx, has demonstrated significant accuracy in predicting recurrence risk for early breast cancer patients. An independent evaluation using data from the phase III PANTHER trial, involving 620 patients, found that nearly 23.5% were classified as low risk.
These low-risk patients exhibited favorable ten-year outcomes, with a 96.1% likelihood of remaining alive and free from breast cancer recurrence. This contrasts with the 76.6% survival rate for those not classified as low risk, highlighting the test's prognostic power.
The myStage Dx test combines artificial intelligence with analysis of digitized histopathology slides and routinely available clinical data. This approach allows for a more precise assessment of individual recurrence risk, assisting oncologists in treatment discussions.
Developed by Spotlight Medical, the CE-IVDR-marked myStage Dx test aims to refine recurrence risk assessment. By identifying patients with a good prognosis despite clinically high-risk disease, it supports informed decision-making regarding additional therapies like CDK4/6 inhibitors, aligning with ASCO guidance.
